Aviragen together with the Georgia State University Research Foundation are jointly working develop and commercialize respiratory syncytial virus (RSV) replication inhibitors discovered by Professor Richard Plemper and his team in the Institute for Biomedical Sciences at Georgia State University. The focus of the collaboration is the RSV L protein, a viral RNA-dependent RNA polymerase that contains multiple enzyme activities required for RSV replication. Learn More.
HUMAN PAPILLOMAVIRUS 6 & 11
BTA074, a protein-protein inhibitor of the interaction between the E1 and E2 proteins of human papillomavirus types 6 and 11, is being evaluated as a topical treatment for genital warts, or condyloma. Learn More.
Laninamivir or LANI, is an inhaled neuraminidase inhibitor for the prevention and treatment influenza A & B. Aviragen and Daiichi Sankyo share commercialization rights to LANI outside of Japan. Aviragen and Daiichi Sankyo intend to collectively pursue a license agreement, or other similar transaction, with regional or global third-party pharmaceutical or biopharmaceutical companies to advance the development and/or commercialization of LANI regionally or globally.
An inhaled neuraminidase inhibitor approved for the treatment and prevention of influenza A and B, is marketed worldwide as Relenza® by GSK. Aviragen receives royalties on sales of Relenza® in countries with issued, non-expired patent claims.
Laninamivir Octanoate (Inavir®)Array
LANI was successfully developed by Daiichi Sankyo in Japan and since 2010 has been marketed there as Inavir® for the treatment of influenza A and B infections. In December 2013, Inavir® was approved for use in the post-exposure prevention of influenza. As part of a commercialization agreement we receive a royalty on net sales in Japan. In April 2016, we entered into a definitive agreement and received a cash payment of $20 million from HealthCare Royalty Partners in exchange for a portion of our royalty rights related to Inavir®.